May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Aakash Desai: We explored the molecular characteristics of KRAS wildtype PDAC
May 16, 2024, 11:47

Aakash Desai: We explored the molecular characteristics of KRAS wildtype PDAC

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:

“In our latest paper, we explored the molecular characteristics of KRAS wildtype PDAC (Pancreatic Ductal Adenocarcinoma) and found actionable genetic variants.

We conducted an in-depth study of 27 patients with KRASWT PDAC, analyzing genetic variants and transcriptomic profiles. Our findings reveal that KRASWT PDAC is distinct from KRASMUT, with potentially actionable genetic mutations.

One notable case involved a patient with a TFG-MET rearrangement who showed remarkable sensitivity to a multi-tyrosine kinase inhibitor, crizotinib, in vitro. This patient participated in a clinical trial, c-MET inhibitor, and achieved a durable partial response.

Our research underscores the importance of precision oncology, highlighting the potential of RNA-seq and other advanced techniques to identify targetable mutations and tailor treatments to individual tumor characteristics.

Precision medicine’s future is now! Clinical Trials are important options, and should be considered standard of care!!”

Source: Aakash Desai/LinkedIn

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Authors: Aakash Desai, Alexander Xiao, Daheui Choi, Merih Toruner, Daniel Walden, Thorvardur Halfdanarson, Steven Alberts, Robert McWilliams, Amit Mahipal, Daniel Ahn, Hani Babiker, Gulnaz Stybayeva, Alexander Revzin, Sani Kizilbash, Alex Adjei, Tanios Bekaii-Saab, Aaron Mansfield, Ryan Carr, and Wen Wee Ma.

Aakash Desai